Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. Vincenti F, et al. Among authors: bresnahan b. Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x. Am J Transplant. 2010. PMID: 20415897 Free article. Clinical Trial.
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F. Vanrenterghem Y, et al. Among authors: bresnahan b. Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb. Transplantation. 2011. PMID: 21372756 Clinical Trial.
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Vincenti F, et al. Among authors: bresnahan b. Am J Transplant. 2012 Jan;12(1):210-7. doi: 10.1111/j.1600-6143.2011.03785.x. Epub 2011 Oct 12. Am J Transplant. 2012. PMID: 21992533 Free article. Clinical Trial.
Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.
Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragón-Ramirez GA, Kothari J, Pupim L, Larsen CP. Rostaing L, et al. Among authors: bresnahan b. Am J Transplant. 2013 Nov;13(11):2875-83. doi: 10.1111/ajt.12460. Epub 2013 Sep 18. Am J Transplant. 2013. PMID: 24047110 Free article. Clinical Trial.
Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L, Bunnapradist S, Grinyó JM, Ciechanowski K, Denny JE, Silva HT Jr, Budde K; Envarsus Study Group. Rostaing L, et al. Am J Kidney Dis. 2016 Apr;67(4):648-59. doi: 10.1053/j.ajkd.2015.10.024. Epub 2015 Dec 22. Am J Kidney Dis. 2016. PMID: 26717860 Free article. Clinical Trial.
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant.
Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Grannas G, Muehlbacher F, O'Connell PJ, Meier-Kriesche HU, Larsen CP. Florman S, et al. Among authors: bresnahan b. Am J Transplant. 2017 Jan;17(1):180-190. doi: 10.1111/ajt.13886. Epub 2016 Jul 12. Am J Transplant. 2017. PMID: 27232116 Free PMC article. Clinical Trial.
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen CP. Florman S, et al. Among authors: bresnahan b. Clin Transplant. 2018 Apr;32(4):e13225. doi: 10.1111/ctr.13225. Epub 2018 Mar 14. Clin Transplant. 2018. PMID: 29461660 Clinical Trial.
Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry.
Larsen CP, Vincenti F, D Kou T, Shadur CA, Bresnahan B, Jordan SC, Woodle ES, Goes N, Vella J, Wojciechowski D, Polinsky MS, Gomez-Caminero A. Larsen CP, et al. Among authors: bresnahan b. Transplant Direct. 2024 May 17;10(6):e1644. doi: 10.1097/TXD.0000000000001644. eCollection 2024 Jun. Transplant Direct. 2024. PMID: 38769981 Free PMC article.
101 results